Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | JNJ-64041809 |
Synonyms | |
Therapy Description |
Opolimogene Capmilisbac (JNJ-64041809) is an attenuated strain of Listeria monocytogenes encoding multiple tumor antigens which may stimulate anti-tumor immune response (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
JNJ-64041809 | JNJ-809|Opolimogene Capmilisbac|ADU-741 | Opolimogene Capmilisbac (JNJ-64041809) is an attenuated strain of Listeria monocytogenes encoding multiple tumor antigens which may stimulate anti-tumor immune response (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02625857 | Phase I | JNJ-64041809 | Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer | Completed | USA | 0 |